CTOs on the Move

CB Scientific

www.cbscientificinc.com

 
A publicly traded (OTC: CBSC) company providing innovative products and services in the ambulatory non-invasive cardiac monitoring space. CB Scientific, Inc., through its US and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
James Ott
 Chief Technology Officer Profile

Similar Companies

RS Medical

RS Medical is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

OrthoCare Orthotics and Prosthetics

OrthoCare Orthotics and Prosthetics is a Leesburg, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hans Rudolph Inc

Hans Rudolph Inc is a Lenexa, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GeneCopoeia

GeneCopoeia is a Germantown, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Corindus

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company`s CorPath® System is the first FDA-cleared medical device to bring robotic-assisted precision to radial, coronary and peripheral procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance stents and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to radial and complex interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement with manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."